Latest News and Press Releases

Vertero strengthens Board of Directors with Independent Chair R. Scott Greer, life sciences veteran, experienced executive, investor, and advisor.

Vertero appointed 5 globally recognized leaders to its Scientific Advisory Board, strengthening the company’s mission to advance innovative therapies.

Vertero appoints Jeffrey Kasten as Chief Business Officer to drive strategic partnerships and accelerate portfolio strategy in neurodegenerative diseases.

Vertero announces initiation of Phase 1 study of VT-5006, a first-in-class selective small molecule therapy for Parkinson’s disease.

Vertero unveils new strategic direction, promising lead asset targeting peripheral drivers of Parkinson’s disease, and Series D financing.

Espoo, Finland, 21 August 2025: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, releases today the Company’s 1H 2025...

NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor Phase 1b/2a study results published in Movement Disorders journalOral,...

Montara Therapeutics received a research grant from The Michael J. Fox Foundation for the development of new therapies targeting LRRK2.

Inflammasome-driven microglial inflammation key to accumulation of toxic phosphorylated alpha-synuclein leading to neurodegeneration and Parkinson's.

ZyVersa's IC 100 blocked microglial NLRP1 inflammasome activation and reduced alpha-synuclein accumulation supporting its potential for Parkinson's Disease